EUCTR2007-006016-33-DE进行中（未招募）1 期
Multicenter Phase II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts after a reduced intensity conditioning regimen for adult patients with acute leukemia - Haplo CD3CD19-RIC
niklinikum Tuebingen0 个研究点目标入组 60 人开始时间: 2008年3月12日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with either ALL or AML being in CR with an indication for allogeneic HCT* but without a suitable HLA-identical donor** within an acceptable time period or with relapse after a preceding allogeneic HCT from an HLA-identical donor
- •Age <65, >18 years
- •Karnofsky Index >60%
- •**AML:high risk patients with one or more of the following risk factors:
- •FLT-3 mutation
- •Complex cytogenetics
- •abn(3q), -5/5q-, -7/7q-, abn(12p), abn(17p)
- •Late CR > induction I
- •Patients in 2.CR
- •Secondary AML
- •ALL: high risk patients with one or more of the following risk factors:
- •Pro-B-ALL
- •Inital WBC >30.000/µL
- •CR after day 46 after Induction II
- •Complex cytogenetics, t(9,22), t(4,11)
- •Early or mature T-ALL
- •Initially refractory patients with late CR
- •Rising MRD level
- •Patients in 2. CR
- •* As acceptable HLA-identical donor not more than 1 antigen mismatch (9/10-Match) or more than 2 allelic mismatches by high-resolution typing are allowed. Critical cases should be discussed with the PI
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with >5% blasts in BM at the time of transplantation
- •Less than 3 months after preceding HCT
- •CNS involvement with disease
- •History of neurologic impairment such as: seizures, severe peripheral neuropathy, signs of leukencephalopathy, CNS infection, multiple intrathecal chemotherapies, CNS irradiation. In case of heavy preatreatment with irradiation or intrathecal chemotherapy pretransplant CNS MRI and neurological consultation are mandatory
- •Fungal infections with radiological progression after receipt of amphotericin B or active triazole for greater than 1 month.
- •Liver function abnormalities with bilirubin >2 mg/dL and elevation of transaminases higher 2x upper limit of normal.
- •Chronic active viral hepatitis
- •Ejection fraction <40 % on echocardiography
- •Patients with > grade II hypertension by CTC criteria
- •Creatinine clearance <50 ml/min
- •Respiratory failure necessitating supplemental oxygen or DLCO <30%
- •Allergy against murine antibodies
- •HIV-Infection
- •Female patients who are pregnant or breast feeding, or adults of reproductive potential not employing an effective method of birth control during study treatment and for at least 12 months thereafter. (Women of childbearing potential must have a negative serum pregnancy test at study entry)
- •Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which could compromise participation in the study
- •Patients with a history of psychiatric illness or condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction)
- •Patients unwilling or unable to comply with the protocol
- •Unable to give informed consent
- •Enrollment in an other trial interfering with the endpoints of this study
研究者
相似试验
已完成
不适用
A phase II study of haploidentical transplantation with post-transplantation cyclophosphamide following myeloablative conditioninghematologic malignanciesJPRN-UMIN000020655JSCT42
已完成
不适用
A phase II study of haploidentical transplantation with post-transplantation cyclophosphamide following reduced-intensity conditioningJPRN-UMIN000020656JSCT36
已完成
不适用
A phase II study of haploidentical transplantation with post-transplantation cyclophosphamide following reduced-intensity conditioningJPRN-UMIN000014408JSCT62
已完成
不适用
A phase II study of haploidentical transplantation with post-transplantation cyclophosphamide following myeloablative conditioningJPRN-UMIN000014406JSCT38
终止
1 期
Haploidentical stem cell transplantation with iCasp9 T cell addback in patients with poor risk haematological malignanciesPatients with high risk acute leukaemia, myelodysplastic syndrome or chronic myeloid leukaemia, who lack a suitable fully human leukocyte antigen (HLA)-matched or single-antigen mismatched donor.Cancer - Leukaemia - Acute leukaemiaCancer - Leukaemia - Chronic leukaemiaBlood - Haematological diseasesACTRN12614000290695Metro North Hospital and Health Service - Royal Brisbane and Womens’ Hospital3